Most vaccines need to be kept at a low temperature from the time they are produced until they are given to patients. This cold-chain system is expensive and difficult to maintain, especially in poor, remote or conflict-affected areas.
Now, a new tetanus and diphtheria vaccine has shown that it can remain effective without refrigeration for more than a year. The development could make it easier to deliver important vaccines to people living in areas with limited electricity and medical infrastructure.
Vaccine Can Stay Stable Without Refrigeration
The new vaccine was developed using a freeze-drying process with trehalose, a type of sugar that helps protect biological materials.
The technology was developed by Stablepharma. The process creates a protective environment around the vaccine components, helping them remain stable even when temperatures rise.
According to the information available, the technology could potentially allow the vaccine to have a shelf life of up to four years, which would be longer than many existing vaccines.
Why Cold Storage Is a Problem
Most vaccines currently need to be stored at temperatures between 2°C and 8°C.
Maintaining these temperatures requires refrigerators, reliable electricity, special transport systems and continuous monitoring. These requirements can be difficult to meet in remote villages and countries with weak healthcare infrastructure.
In areas affected by war or natural disasters, keeping vaccines cold can become even more difficult.
If the cold chain breaks, vaccines may lose their effectiveness and may no longer be safe or suitable for use.
Few Vaccines Can Avoid Refrigeration
Only a small number of vaccines can currently remain outside refrigeration for extended periods.
Some vaccines can tolerate higher temperatures for a limited amount of time, but long-term stability remains a major challenge.
The new technology could help overcome this problem by allowing vaccines to remain stable for much longer without constant refrigeration.
Could Help Reach More People
A vaccine that does not depend heavily on cold storage could make distribution much easier.
Health workers could potentially transport vaccines to remote communities without relying on expensive refrigerated vehicles and storage facilities.
This could be particularly useful in areas where electricity supplies are unreliable or where healthcare facilities are far from major cities.
Lower Costs and Easier Distribution
Reducing the need for cold storage could also lower some of the costs involved in vaccine transportation and storage.
Healthcare workers could have more flexibility when planning vaccination campaigns, especially in difficult-to-reach areas.
It could also make it easier to keep vaccine supplies available for emergencies.
A Possible Change in Vaccine Distribution
The development represents an important step toward making vaccines more stable at higher temperatures.
If the technology is successfully approved and used on a wider scale, it could reduce dependence on traditional cold-chain systems and help vaccines reach communities that are currently difficult to serve.
For millions of people living in remote, poor or crisis-affected regions, easier vaccine storage could make life-saving immunisation more accessible